Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isoetharine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 3/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.86 |
| ▸ | MAPT | P10636 | 8/20 | 0.86 |
| ▸ | TSHR | P16473 | 6/20 | 0.86 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.86 |
| ▸ | LMNA | P02545 | 5/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.86 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.86 |
| ▸ | BLM | P54132 | 3/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.86 |
| ▸ | THPO | P40225 | 2/20 | 0.86 |
| ▸ | GAA | P10253 | 2/20 | 0.86 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoetharine SCHEMBL56515 | 1.00 | ADRB2 (1.00) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| Isoetharine SCHEMBL29515330 | 1.00 | ADRB2 (1.00) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| Isoetharine SCHEMBL56516 | 1.00 | ADRB2 (1.00) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| Isoetharine SCHEMBL21252711 | 1.00 | ADRB2 (1.00) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| Isoetharine SCHEMBL3218412 | 1.00 | ADRB2 (1.00) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| Isoetharine SCHEMBL211343 | 0.98 | ADRB2 (0.97) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| Isoetharine SCHEMBL29380912 | 0.93 | KDM4E (1.00) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| Isoetharine SCHEMBL212005 | 0.93 | KDM4E (1.00) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| Isoetharine SCHEMBL2407556 | 0.93 | KDM4E (1.00) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| Isoetharine SCHEMBL4377543 | 0.92 | KDM4E (0.97) | ADRB2PTGS2OPRK1SLC6A3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9351947-B2 | Use of catecholamines and related compounds as anti-angiogenic agents | NATIONAL RESEARCH COUNCIL OF CANADA | 2016-05-31 | — | — | US | claimed |
| EP-2117524-B1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NAT RES COUNCIL CANADA (CA) | 2019-08-14 | — | — | EP | disclosed |
| US-20170027889-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20170027888-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-9351947-B2 | Use of catecholamines and related compounds as anti-angiogenic agents | NATIONAL RESEARCH COUNCIL OF CANADA | 2016-05-31 | — | — | US | disclosed |
| US-20100069401-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027888-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | ADRB3, ADRB1, ADRA1D | ADRB2 4/4885PTGS2 2566/4885OPRK1 102/4885 |
| US-20170027889-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | SLC6A2, VEGFA, COMT | ADRB2 7/4885PTGS2 1131/4885OPRK1 331/4885 |
| US-20100069401-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | ADRB2, ADRB1, SLC6A2 | ADRB2 1/4885PTGS2 830/4885OPRK1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.